A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa

Mugnier, Pierre; Dubrous, P.; Casin, I.; Arlet, Guillaume; Collatz, E.

doi:10.1128/aac.40.11.2488

Cited by 74 publications

(38 citation statements)

References 46 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Loss of permeability [25] and active antimicrobial efflux may affect other types of drugs such as aminoglycosides or quinolones [26,27]. This may be complemented with alterations in DNA gyrase [28] and the presence of aminoglycoside-modifying enzymes, leading to the emergence of multidrug-resistant P. aeruginosa (MDR-PSA) [13,18,[29][30][31][32][33][34][35][36][37][38][39] against which there are very few therapeutic options, such as polymyxins [30,[40][41][42].…”

mentioning

confidence: 99%

Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999

Gales¹,

Jones²,

Turnidge³

et al. 2001

CLIN INFECT DIS

296

234

View full text Add to dashboard Cite

During 1997-1999, a total of 70,067 isolates (6631 Pseudomonas aeruginosa isolates) were analyzed in the SENTRY program by geographic region and body site of infection. The respiratory tract was the most common source of P. aeruginosa. P. aeruginosa isolation rates increased during the study interval. Europe was the only region to show a significant decline in beta-lactam and aminoglycoside susceptibility rates. There was a reduction in the rates of susceptibility of Canadian isolates to imipenem and of Latin American isolates to meropenem. A total of 218 multidrug-resistant P. aeruginosa isolates (MDR-PSA; resistant to piperacillin, ceftazidime, imipenem, and gentamicin) were observed; MDR-PSA occurrence rates (percentages of all isolates) ranged from 8.2% (Latin America) to 0.9% (Canada). No antimicrobial inhibited >50% of MDR-PSA strains. Molecular characterization of selected, generally resistant strains was performed. Isolates showing unique ribogroups were found in Europe, Latin America, and the United States, but clonal spread was documented in several medical centers.

show abstract

mentioning

confidence: 99%

Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999

Gales¹,

Jones²,

Turnidge³

et al. 2001

CLIN INFECT DIS

296

234

View full text Add to dashboard Cite

show abstract

“…To date, three classes of enzymes have been described, penicillinase-derivatives (class A), metallo-β-lactamases (class B) and oxacillinases (class D). Class A enzymes are encoded on plasmids and may be horizontally transmitted from other enteric Gram-negative bacteria (16, 17). PA strains expressing class A enzymes develop resistance to ureidopenicillins, CAZ, cefpirome, CFP and susceptibility to carboxy- or ureidopenicillin/inhibitor combinations.…”

Section: Discussionmentioning

confidence: 99%

Rate of Isolation and Trends of Antimicrobial Resistance of Multidrug ResistantPseudomonas Aeruginosafrom Otorrhea in Chronic Suppurative Otitis Media

Lee

Park

Kim

et al. 2012

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

ObjectivesTo assess the rate of isolation of Pseudomonas aeruginosa (PA) and multidrug-resistant PA (MDR-PA) from patients with chronic suppurative otitis media (CSOM) otorrhea and the annual trend of antibiotic-resistance.MethodsOtorrhea samples were collected aseptically from 1,598 CSOM patients. The rate of bacterial isolation and the results of antibiotic susceptibility testing were evaluated retrospectively.ResultsThe PA isolation rate from CSOM otorrhea was 24.4%. Of the 398 isolated strains tested for their susceptibilities to 10 antibiotics, 395 strains showed definitive results. Of these, 183 (46.3%) were susceptible to whole antibiotics and 212 (53.7%) was resistant to more than 1 antibiotics, with the frequency of antibiotics-resistance increasing significantly over time. Although strains susceptible to all antibiotics decreased over time, the rate of isolation of MDR-PA did not change significantly. Resistance to aminoglycosides and quinolones was higher than to other antibiotics and significantly increased over time, whereas resistance to other antibiotics showed no trend.ConclusionMDR-PA, assessed using five individual antibiotics and six antibiotic-classes, showed no tendency to increase or decrease over time. This may have been due to increased concern about antibiotic-resistant bacterial strains, leading to improved infection control within hospitals and healthcare centers.

show abstract

“…aeruginosa exhibits a far more complex and extensive repertoire of β-lactamase genes and gene products than either H. influenzae or M. catarrhalis ( Table 2). Plasmid localization has been shown for most of the genes encoding the TEM and SHV enzymes, whereas genes encoding VEB-and GES-type enzymes are usually located in class 1 integrons, and an additional route of dissemination is provided by some genes being on transposons [53][54][55][56]. The class A extended spectrum β-lactamases (ESBLs) include TEM, SHV, PER, VEB, GES/IBC, BEL and CTX-M types [45][46][47][48][49][50][51][52], all with low common genetic identity but with similar hydrolysis profiles.…”

Section: Chromosomalmentioning

confidence: 99%

Mechanisms of Bacterial Resistance to Antibiotics in Infections of COPD Patients

Kyd¹,

McGrath²,

Krishnamurthy

2011

CDT

View full text Add to dashboard Cite

A key characteristic of airway inflammation in chronic obstructive pulmonary disease (COPD) is the persistent presence of bacteria in the lower airways. The most commonly isolated bacteria in the lower respiratory tract of COPD patients are nontypeable Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, with growing evidence of the significance of Pseudomonas aeruginosa infections in severe COPD disease. This review focuses on the antibiotic resistant mechanisms associated with the gram-negative bacteria H. influenzae and M. catarrhalis and comparison with P. aeruginosa infection because of the recent evidence of its significance in patients with severe COPD disease. These mechanisms of resistance to β-lactams in H. influenzae and M. catarrhalis are mostly associated with serine β-lactamases of class A type, whereas P. aeruginosa strains exhibit a much broader repertoire with class A-D type mechanisms. Other mechanisms of antibiotic resistance include membrane permeability, efflux pump systems and mutations in antimicrobial targets. Antimicrobial resistance within biofilm matrices appears to be different to the mechanisms observed when the bacteria are in the planktonic state. P. aeruginosa exhibits a more numerous and diverse range of antimicrobial resistance mechanisms in comparison to M. catarrhalis and H. influenzae. The recognition that P. aeruginosa is associated with exacerbations in patients with more severe COPD and that turnover in infecting strains is detected (unlike in cystic fibrosis patients), then further investigation is required to better understand the contribution of antimicrobial resistance and other virulence mechanisms to poor clinical outcomes to improve therapeutic approaches.

show abstract

A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa

Cited by 74 publications

References 46 publications

Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999

Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999

Rate of Isolation and Trends of Antimicrobial Resistance of Multidrug ResistantPseudomonas Aeruginosafrom Otorrhea in Chronic Suppurative Otitis Media

Mechanisms of Bacterial Resistance to Antibiotics in Infections of COPD Patients

Contact Info

Product

Resources

About